Valuation: Lakefront Biotherapeutics NV

Market Cap 1.59B 1.83B 1.48B 1.36B 2.56B 174B 2.6B 17.42B 6.84B 86.82B 6.86B 6.71B 291B P/E 2026 *
-11.3x
P/E 2027 * -8.53x
Enterprise Value -395M -455M -368M -338M -638M -43.39B -648M -4.34B -1.7B -21.6B -1.71B -1.67B -72.44B EV / Sales 2026 *
-27.7x
EV / Sales 2027 * -8.8x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day-1.00%
1 week-3.71%
Current month-9.00%
1 month-9.00%
3 months-1.16%
6 months-16.10%
Current year-14.79%
1 week 23.66
Extreme 23.66
25.26
1 month 23.66
Extreme 23.66
27.12
Current year 22.62
Extreme 22.62
30.72
1 year 22.62
Extreme 22.62
32.74
3 years 20
Extreme 20
40.26
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Director

137 0.0002%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-3.71%-17.55%-36.00% 1.83B
-1.40%+2.59%-1.71%+11.28% 49.37B
-0.90%+13.34%+26.87%+5.38% 39.14B
-2.03%-0.13%+407.08%+619.95% 40.85B
-1.80%-3.36%+4.59%+47.02% 35.81B
-1.74%+8.42%+8.85%+48.87% 30.5B
-2.55%-3.27% - - 16.55B
-0.22%-3.96%+35.19%+128.13% 16.14B
-0.98%+0.20%-1.83%-33.94% 12.77B
-0.64%+3.09%+3.15%+9.37% 13.71B
Average -1.25%+4.78%+51.62%+88.90% 25.67B
Weighted average by Cap. -1.34%+6.64%+77.41%+128.96%

Financials

2026 *2027 *
Net sales 14.24M 16.38M 13.25M 12.17M 22.98M 1.56B 23.34M 156M 61.32M 779M 61.52M 60.17M 2.61B 46.09M 53.02M 42.9M 39.39M 74.38M 5.06B 75.53M 506M 198M 2.52B 199M 195M 8.45B
Net income -811M -933M -755M -693M -1.31B -89.03B -1.33B -8.89B -3.49B -44.32B -3.5B -3.43B -149B -238M -274M -221M -203M -384M -26.11B -390M -2.61B -1.02B -13B -1.03B -1B -43.59B
Net Debt -1.98B -2.28B -1.85B -1.69B -3.2B -218B -3.25B -21.76B -8.54B -108B -8.57B -8.38B -364B -1.99B -2.29B -1.86B -1.7B -3.22B -219B -3.27B -21.87B -8.58B -109B -8.61B -8.42B -365B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
26-07-31 23.86 -1.00% 94,021
26-07-30 €24.10 -1.79% 87,672
26-07-29 €24.54 -0.65% 61,709
26-07-28 €24.70 -0.40% 56,583
26-07-27 €24.80 +1.22% 70,144
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
24.10EUR
Average target price
30.28EUR
Spread / Average Target
+25.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock